


ARHI
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT

@arhiusa Advanced Research for Health Improvement

1172 Goodlette Frank Road North, Suite # 201, Naples, Florida 34102

(239) 230-2021 info@arhiusa.com www.arhiusa.com

ACHIEVEMENTS



ARHI and Principal Investigator Dr. Julian J. Javier contribute to groundbreaking STEM CELL CLINICAL TRIAL FOR AGING FRAILTY PUBLISHED IN CELL STEM CELL

ARHI announced the publication of a **Phase 2b clinical trial in Cell Stem Cell** evaluating laromestrocel, an investigational stem cell therapy for age-related frailty. Led in part by **Principal Investigator Dr. Julian J. Javier**, the randomized, placebo-controlled study in 148 older adults demonstrated meaningful improvements in physical endurance, including increased 6-minute walk distance, along with enhanced patient-reported function.

The findings also suggest a potential biological mechanism tied to treatment response, **marking a significant step forward in regenerative medicine for frailty**. This milestone reinforces ARHI's commitment to advancing innovative, evidence-based therapies aimed at improving health outcomes in aging populations.

Clinical Advances in Aging Frailty: ARHI & Dr. Julian J. Javier in Cell Stem Cell Publication

PHASE 2B CLINICAL TRIAL OF LAROMESTROCEL SHOWS PROMISING RESULTS FOR AGING FRAILTY

ADVANCED RESEARCH FOR HEALTH IMPROVEMENT (ARHI) AND DR. JULIAN J. JAVIER PARTICIPATED IN A LANDMARK CELL STEM CELL PUBLICATION REPORTING RESULTS FROM A PHASE 2B CLINICAL TRIAL OF LAROMESTROCEL.

THE STUDY DEMONSTRATED MEANINGFUL IMPROVEMENTS IN PHYSICAL PERFORMANCE OUTCOMES, REPRESENTING AN ENCOURAGING STEP FORWARD IN REGENERATIVE MEDICINE AND HEALTHY AGING RESEARCH.

ARHI 239-230-2021 arhiusa.com

CARDAMYST™ now approved SELF-ADMINISTERED TREATMENT



ARHI Research Contributes to CARDAMYST™, the First FDA-Approved Self-Administered Treatment for PSVT.

Milestone Pharmaceuticals announced the U.S. availability of CARDAMYST™ (etripamil) nasal spray, marking the commercial launch of its first approved product. **The therapy is now accessible through retail pharmacies and is designed as a self-administered, rapid-response treatment for adults** experiencing episodes of paroxysmal supraventricular tachycardia (PSVT), a type of abnormal heart rhythm.

CARDAMYST represents the **first new FDA-approved treatment for PSVT in over 30 years** and offers patients the ability to manage episodes outside of emergency settings. **The launch is supported by a national commercial rollout and patient assistance programs**, including reimbursement support and potential copay reductions, aimed at improving access and affordability.

ADVANCING INNOVATION IN CARDIOVASCULAR CARE.

ADVANCED RESEARCH FOR HEALTH IMPROVEMENT (ARHI) PLAYED A CRITICAL ROLE IN THE RESEARCH THAT CONTRIBUTED TO THE DEVELOPMENT OF CARDAMYST™ (ETRIPAMIL) NASAL SPRAY – THE FIRST AND ONLY FDA-APPROVED SELF-ADMINISTERED TREATMENT FOR ADULTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT).

ARHI 239-230-2021 arhiusa.com

ACTIVITIES

FEBRUARY 23-24

Eli Lilly GZMG Investigator Engagement Meeting to Advance Opioid Use Disorder Clinical Research



ARHI at the Eli Lilly GZMG Investigator Engagement Meeting

ADVANCING CLINICAL RESEARCH IN OPIOIDS USE DISORDER (OUD)

WE'RE PROUD TO ANNOUNCE THAT DR. LEONARD LADO, PRINCIPAL INVESTIGATOR, AND JUAN C. RAMOS, M.S., CLINICAL TRIALS MANAGER AT ARHI, ATTENDED THE ELI LILLY GZMG INVESTIGATOR ENGAGEMENT MEETING ON FEBRUARY 23-24, 2026, IN ATLANTA, GA.

THE MEETING CENTERED ON THE UPCOMING OPIOID USE DISORDER

ARHI 239-230-2021 arhiusa.com

ARHI representatives, **Principal Investigator Dr. Leonard Lado** and **Clinical Trials Manager C. Ramos, M.S.**, participated in the **Eli Lilly GZMG Investigator Engagement Meeting** held March 23-24, 2026, in Atlanta, GA. The meeting brought together investigators, research teams, and sponsor representatives to discuss the development of an upcoming clinical trial focused on **Opioid Use Disorder (OUD)**, including trial design, operations, and participant engagement strategies.

Through this collaboration, ARHI gained valuable insights into protocol development, regulatory considerations, and multi-site coordination, **reinforcing its commitment to research excellence and patient-centered clinical trials**. ARHI continues to expand its role in advancing innovative, multi-center research aimed at addressing high-impact health conditions.

MARCH 31st The Importance of Diversity and Inclusion in Clinical Trials: Current Trends and Enrolling Trials




THE IMPORTANCE OF DIVERSITY AND INCLUSION IN CLINICAL TRIALS: CURRENT TRENDS AND ENROLLING TRIALS

ADVANCED RESEARCH FOR HEALTH IMPROVEMENT (ARHI) PRESENTS UPDATES IN CLINICAL RESEARCH TRIALS.

JOIN DR. LEONARDO PEREZ TUESDAY, MARCH 31 / 6:30 P.M. ET - 8:30 P.M. ET

THE HAMPTON SOCIAL - NAPLES 9114 STRADA PLACE, NAPLES, FL 34108

ARHI 239-230-2021 arhiusa.com



ADVANCING INCLUSIVE HEALTHCARE ARHI LEADS THE CONVERSATION IN NAPLES WITH DR. PEREZ



ARHI

ARHI hosted a community-centered event at **The Social Hampton in Naples** focused on **promoting diversity and inclusion in clinical trials**. The event brought together research professionals, healthcare providers, and community advocates to discuss ways to improve representation and expand access to innovative treatments.

Dr. Perez underscored the importance of diverse participation in developing safe and effective therapies for all populations, while addressing key barriers such as low awareness, mistrust, and limited access.

Attendees explored practical strategies to enhance inclusion, including **community engagement, culturally competent communication, multilingual outreach, and stronger partnerships with local providers**. The program also featured presentations of actively enrolling clinical trials by **Dr. Leonard Lado, Dr. Tracey Roth, and Dr. Shahzaib Mirza**, along with contributions from the Nurse Practitioner Council of Naples. ARHI reaffirmed its commitment to advancing inclusive research and closed the event with a call to action to prioritize diversity in future studies.

NEW STUDIES OPENED

In Q3, ARHI successfully launched **new clinical trials in Naples, Florida**, strengthening our role as a trusted provider of advanced medical research and accessible patient care in Southwest Florida.

Community Impact:
Free, advanced medical oversight for eligible residents.
Compensation per participant to help cover time and travel.

Expanded outreach in Naples and neighboring communities, including Immokalee, Bonita Springs, Marco Island, and Fort Myers.

Strategic Impact:
These trials reaffirm our **commitment to delivering patient-focused innovation**, creating local health benefits while contributing valuable data to **shape future global treatments**.

Outlook:
We expect to build on this momentum by expanding outreach and strengthening partnerships with local healthcare providers, **ensuring that more patients can benefit from new care options and contribute to medical breakthroughs**.

HOW OBESITY AND KNEE OSTEOARTHRITIS AFFECT DAILY LIFE?

Living with obesity and knee osteoarthritis can make simple things, like walking or climbing stairs, hurt and wear you out. Carrying extra weight puts more pressure on your knees, which can make pain, swelling, and joint damage worse.

This often leads to stiffness, swelling, and limited movement, making it harder to stay active or manage weight. Over time, pain and mobility loss can affect independence, mood, and quality of life.

NOW ENROLLING FOR CLINICAL TRIAL

QUALIFIED PARTICIPANTS MUST:

- Be at least 18 y/o at the time of signing the informed consent.
- Body mass index (BMI) > 27.0 kg/m² at screening.
- Clinical diagnosis of knee osteoarthritis (OA) with radiographic changes.
- Participant must have a desire and be committed to lose at least 25% of their body weight.

Additional (inclusion and exclusion) criteria may apply, and will be evaluated at the clinical study site.

QUALIFIED PARTICIPANTS MAY:

- Receive compensation up to \$3,000 if all visits are completed.
- Receive access to study medication.
- Have access to study doctors.

Inclusion/Exclusion criteria may apply, and will be evaluated with you at the clinical site.

Julian J. Javier, M.D. Principal Investigator

ARHI Corp HQ
1172 Goodlette Frank Road North, Suite # 201
Naples, Florida 34102

(239) 230-2021 arhiusa.com

Obesity and Osteoarthritis of the Knee Clinical Study

Research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose weight and reduce pain.

Opioid Abuse Disorder (OUD) Clinical Study

A study to evaluate the efficacy and safety of buprenatpe as adjunctive treatment to buprenorphine with or without naloxone in early recovery of participants with opioid use.

ARE YOU CHAINED TO OPIOIDS USE DISORDER? (OUD)

Opioid Use Disorder (OUD) is a medical condition defined as the chronic use of opioids that causes clinically significant distress or impairment.

QUALIFIED PARTICIPANTS MUST:

- Are outpatients 18 to 75 years of age, inclusive, at the time of signing the informed consent.
- Have a current mild, moderate or severe OUD diagnosis.
- Are intermittently using opioids such as, but not limited to, prescription opioids, buprenorphine, or heroin.
- Provides at least 1 explicit positive UDS.

Additional (inclusion and exclusion) criteria may apply, and will be evaluated at the clinical study site.

QUALIFIED PARTICIPANTS MAY:

- Receive compensation up to \$4,000 if all visits are completed.
- Receive access to study medication.
- At the time of screening, agrees to remain on buprenorphine.

Leonard Lado, M.D. Principal Investigator

ARHI Corp HQ
1172 Goodlette Frank Road North, Suite # 201
Naples, Florida 34102

arhiusa.com 239-230-2021

REWRITE YOUR HEART'S FUTURE

Now enrolling in a clinical study for the prevention of MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) in patients with prior or at risk of Atherosclerotic Cardiovascular Diseases.

QUALIFIED PARTICIPANTS MUST:

- Participants must be 18 years of age when signing the informed consent.
- Have an LDL laboratory level of > 175 nmol/L.
- Had a prior or are at risk for a first ASCVD event.
- Most recent ASCVD event must have occurred between 90 days and 10 years before the 1st screening.
- Be willing to participate for the full duration of the study, attend scheduled study visits, and follow all study procedures.

Additional (inclusion and exclusion) criteria may apply, and will be evaluated at the clinical study site.

QUALIFIED PARTICIPANTS MAY:

- Receive compensation up to \$4000 if all visits are completed.
- Receive access to study medication.
- Have access to study doctors.

Inclusion/Exclusion criteria may apply, and will be evaluated with you at the clinical site.

Julian J. Javier, M.D. Principal Investigator

ARHI Corp HQ
1172 Goodlette Frank Road North, Suite # 201
Naples, Florida 34102

(239) 230-2021 arhiusa.com

Prevention of Major Adverse Cardiovascular Events Clinical Trial

A Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a)

ACTIVE STUDIES UPDATES

Our site successfully conducted 155 patient visits from January through March 2026. All of our coordinators: Julian, Maria Claudia, Ismery, and Lesky have worked diligently to achieve the goals set for all ongoing trials at this site. Please join the management team in congratulating them and recognizing their hard work and dedication!

COPD on the Heart (COPD)
Enrolling Now!

COPD on the Heart (COPD)
Enrolling Now!

Atherosclerotic Cardiovascular Disease (ASCVD)
Enrolling Now!

For more info:



ARHI
ADVANCED RESEARCH FOR HEALTH IMPROVEMENT

@arhiusa Advanced Research for Health Improvement

1172 Goodlette Frank Road North, Suite # 201, Naples, Florida 34102

(239) 230-2021 info@arhiusa.com www.arhiusa.com